AI Accurately Identifies Normal and Abnormal Chest X-rays

An artificial intelligence (AI) tool can accurately identify normal and abnormal chest X-rays in a clinical setting, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).

Chest X-rays are used to diagnose a wide variety of conditions to do with the heart and lungs. An abnormal chest X-ray can be an indication of a range of conditions, including cancer and chronic lung diseases.

An AI tool that can accurately differentiate between normal and abnormal chest X-rays would greatly alleviate the heavy workload experienced by radiologists globally.

“There is an exponentially growing demand for medical imaging, especially cross-sectional such as CT and MRI,” said study co-author Louis Lind Plesner, M.D., from the Department of Radiology at the Herlev and Gentofte Hospital in Copenhagen, Denmark. “Meanwhile, there is a global shortage of trained radiologists. Artificial intelligence has shown great promise but should always be thoroughly tested before any implementation.”

For this retrospective, multi-center study, Dr. Plesner and colleagues wanted to determine the reliability of using an AI tool that can identify normal and abnormal chest X-rays.

Researchers used a commercially available AI tool to analyze the chest X-rays of 1,529 patients from four hospitals in the capital region of Denmark. Chest X-rays were included from emergency department patients, in-hospital patients and outpatients. The X-rays were classified by the AI tool as either “high-confidence normal” or “not high-confidence normal” as in normal and abnormal, respectively.

Two board-certified thoracic (chest) radiologists were used as the reference standard. A third radiologist was used in cases of disagreements, and all three physicians were blinded to the AI results.

Of the 429 chest X-rays that were classified as normal, 120, or 28%, were also classified by the AI tool as normal. These X-rays, or 7.8 % of all the X-rays, could be potentially safely automated by an AI tool. The AI tool identified abnormal chest X-rays with a 99.1% of sensitivity.

“The most surprising finding was just how sensitive this AI tool was for all kinds of chest disease,” Dr. Plesner said. “In fact, we could not find a single chest X-ray in our database where the algorithm made a major mistake. Furthermore, the AI tool had a sensitivity overall better than the clinical board-certified radiologists.”

According to the researchers, further studies could be directed toward larger prospective implementation of the AI tool where the autonomously reported chest X-rays are still reviewed by radiologists.

The AI tool performed especially well at identifying normal X-rays of the outpatient group at a rate of 11.6%. This suggests that the AI model would perform especially well in outpatient settings with a high prevalence of normal chest X-rays.

“Chest X-rays are one of the most common imaging examination performed worldwide,” Dr. Plesner said. “Even a small percentage of automatization can lead to saved time for radiologists, which they can prioritize on more complex matters.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”